Bispecific antibodies that target tumor antigens, fibroblast activation protein on stromal cells, or other receptors such as 4–1BB can also cross-link CD40 agonists, promoting antitumor immunity in the tumor microenvironment [3]. The gene discussed is CD40; the disease is neoplasm.